Viking Therapeutics - Press Releases http://ir.vikingtherapeutics.com/ Viking Therapeutics Presents Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol in Oral Late-Breaker Presentation at The Liver MeetingĀ® 2018 http://ir.vikingtherapeutics.com/2018-11-12-Viking-Therapeutics-Presents-Results-from-Phase-2-Study-of-VK2809-in-Patients-with-Non-Alcoholic-Fatty-Liver-Disease-NAFLD-and-Elevated-LDL-Cholesterol-in-Oral-Late-Breaker-Presentation-at-The-Liver-Meeting-R-2018 Study Achieves Primary Endpoint, Demonstrating Statistically Significant LDL-C Reductions in Patients Receiving VK2809 at Week 12 Mon, 12 Nov 2018 18:55:00 -0500 http://ir.vikingtherapeutics.com/2018-11-12-Viking-Therapeutics-Presents-Results-from-Phase-2-Study-of-VK2809-in-Patients-with-Non-Alcoholic-Fatty-Liver-Disease-NAFLD-and-Elevated-LDL-Cholesterol-in-Oral-Late-Breaker-Presentation-at-The-Liver-Meeting-R-2018 Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update http://ir.vikingtherapeutics.com/2018-11-07-Viking-Therapeutics-Reports-Third-Quarter-2018-Financial-Results-and-Provides-Corporate-Update Conference call scheduled for 4:30 p.m. ET today Wed, 07 Nov 2018 16:05:00 -0500 http://ir.vikingtherapeutics.com/2018-11-07-Viking-Therapeutics-Reports-Third-Quarter-2018-Financial-Results-and-Provides-Corporate-Update Viking Therapeutics to Report Financial Results for Third Quarter 2018 on November 7, 2018 http://ir.vikingtherapeutics.com/2018-10-31-Viking-Therapeutics-to-Report-Financial-Results-for-Third-Quarter-2018-on-November-7-2018 Conference Call Scheduled for Wednesday, November 7 at 4:30 p.m. Eastern Time Wed, 31 Oct 2018 07:35:00 -0400 http://ir.vikingtherapeutics.com/2018-10-31-Viking-Therapeutics-to-Report-Financial-Results-for-Third-Quarter-2018-on-November-7-2018 Viking Therapeutics Announces Data from In Vivo Study of VK2809 Presented at Oral Plenary Session of the 88th Annual Meeting of American Thyroid Association (ATA) http://ir.vikingtherapeutics.com/2018-10-08-Viking-Therapeutics-Announces-Data-from-In-Vivo-Study-of-VK2809-Presented-at-Oral-Plenary-Session-of-the-88th-Annual-Meeting-of-American-Thyroid-Association-ATA VK2809 Treatment Leads to Rapid Reduction in Steatosis, Inflammation and Liver Size in Mouse Model of Glycogen Storage Disease Type Ia (GSD Ia) Mon, 08 Oct 2018 07:02:00 -0400 http://ir.vikingtherapeutics.com/2018-10-08-Viking-Therapeutics-Announces-Data-from-In-Vivo-Study-of-VK2809-Presented-at-Oral-Plenary-Session-of-the-88th-Annual-Meeting-of-American-Thyroid-Association-ATA Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected for Oral Late-Breaker Presentation at The Liver MeetingĀ® 2018 http://ir.vikingtherapeutics.com/2018-10-04-Viking-Therapeutics-Announces-VK2809-Phase-2-Study-Results-Selected-for-Oral-Late-Breaker-Presentation-at-The-Liver-Meeting-R-2018 Presentation to Highlight Positive 12-Week Data for Novel, Liver-Selective Thyroid Receptor Beta Agonist in Patients with Non-Alcoholic Fatty Liver Disease and Elevated LDL-Cholesterol Thu, 04 Oct 2018 07:02:00 -0400 http://ir.vikingtherapeutics.com/2018-10-04-Viking-Therapeutics-Announces-VK2809-Phase-2-Study-Results-Selected-for-Oral-Late-Breaker-Presentation-at-The-Liver-Meeting-R-2018